Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damon Inc.DMN · Entity 85031 | Director · Chief Financial Officer | November 13, 2024 | November 15, 2024 |
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Director | May 15, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damon Inc.
Report date November 13, 2024 · Filed November 15, 2024
This filing explicitly reported no securities owned.
Lexaria Bioscience Corp.
Report date May 15, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2030-05-15 | Direct | 11,000 |
Reported balance
After 2025-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-15 · Grant · Acquired 11,000 · Balance 11,000 |
| common sharesSEC Table I · non-derivative | Direct | 13,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Enertopia Corp.
Report date July 31, 2017 · Filed July 31, 2017
Section 16 reporting ended · disclosed 2017-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,201,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,201,000 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2018-02-14 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 100,000 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2019-05-20 | Direct | 1,100,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,100,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2018-11-05 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 250,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2019-11-03 | Direct | 750,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 750,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2020-10-23 | Direct | 1,350,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,350,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2022-01-20 | Direct | 1,850,000 |
Reported balance
Holding disclosure · report date 2017-07-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,850,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 16, 2025 16:44 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 11,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001348362-25-000006 · primary_doc.xml · derivative · entry 2 Bhullar Baljinder · CIK 0001401225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2030-05-15 Read SEC document |
| January 20, 2017 Filed Jan 20, 2017 16:48 UTC | Enertopia Corp. ENRT · Entity 8684 | PurchaseStock Options · Derivative | 500,000 | $0.05 Strike: $0.07 | $25,000.00 |
DisclosureSEC source: 0001401225-17-000001 · primary_doc.xml · derivative · entry 7 Bhullar Baljinder · CIK 0001401225 · Director · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,850,000 Underlying: Common Shares · 500,000 shares Expires 2022-01-20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.